FDA Begins Reviewing Henlius’ Trastuzumab

The Oncology Biosimilar Is Already Approved In China And The EU

 
• By Rosalind Rei
  
Immunohistochemistry image for HER2 shows positive cell membrane staining in this infiltrating ductal carcinoma.
Trastuzumab Treats HER2-2 Breast Cancers • Source: Shutterstock

More from Regulation

More from Policy & Regulation